You are here: Industry Insights > FASENRA

News List

FDA-approved drug effectively treats rare chronic immune disorder firstwordpharma
April 04, 2019
A drug approved to treat a severe form of asthma dramatically improved the health of people with rare chronic immune disorders called hypereosinophilic syndromes (HES) in whom other treatments were ineffective or intolerable.
AstraZeneca’s Fasenra puts more pressure on GSK’s Nucala with expanded NICE backing fiercepharma
January 08, 2019
Back in mid-2018, AstraZeneca’s Fasenra hit a speed bump as England’s drug cost watchdog recommended it only when GlaxoSmithKline’s rival asthma drug Nucala wasn’t appropriate. But now, the AZ drug is in the fast lane thanks to an expanded recommendation.
AZ’ Fasenra shows long-term efficacy in eosinophilic asthma pharmatimes
September 20, 2018
AstraZeneca has unveiled data from a Phase III extension trial highlighting the efficacy of biologic Fasenra as an add-on maintenance treatment...
Fasenra Shows Consistent Safety, Efficacy in Long-Term in Severe Eosinophilic Asthma Trial americanpharmaceuticalreview
September 20, 2018
AstraZeneca announced results from the Phase III extension BORA trial evaluating the long-term safety and efficacy of Fasenra (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who had previously completed one of
NICE backs AZ’ asthma biologic Fasenra pharmatimes
July 17, 2018
AstraZeneca’s biologic Fasenra will likely be funded on the NHS as a treatment for people with severe eosinophilic asthma.
Fasenra Does Not Meet Primary Endpoint in Severe COPD Study americanpharmaceuticalreview
May 18, 2018
AstraZeneca and MedImmune announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
AZ’s Fasenra stumbles in P3 for COPD pharmafile
May 15, 2018
AstraZeneca’s Fasenra arrived later on the scene than GSK rival med, Nucala, and so it needed to quickly rack up indications to mount a serious challenge – in COPD,
FDA approves Fasenra for severe eosinophilic asthma europeanpharmaceuticalreview
November 17, 2017
The FDA has approved Fasenra for the add-on maintenance treatment of patients with severe asthma aged 12 years and older…
FDA Approves FASENRA for Severe Eosinophilic Asthma americanpharmaceuticacreview
November 16, 2017
FASENRA is not approved for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.

Previous page 1 2 Next page